Alk1 receptor and ligand antagonists and uses thereof
US-2017354731-A1 · Dec 14, 2017 · US
Compositions comprising ALK1-ECD protein
US10059756B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10059756-B2 |
| Application number | US-201213447091-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 13, 2012 |
| Priority date | Nov 2, 2006 |
| Publication date | Aug 28, 2018 |
| Grant date | Aug 28, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. Additionally, the disclosure demonstrates that inhibitors of ALK1 may be used to increase pericyte coverage in vascularized tissues, including tumors and the retina. The disclosure also identifies ligands for ALK1 and demonstrates that such ligands have pro-angiogenic activity, and describes antibodies that inhibit receptor-ligand interaction.
First claim
Opening claim text (preview).
We claim: 1. A pharmaceutical preparation comprising an ALK1-ECD protein, wherein the ALK1-ECD protein comprises an extracellular domain that is at least 80% identical to amino acids 22-118 of SEQ ID NO: 1, wherein at least 90% of the ALK1-ECD protein is present in a dimeric form, and wherein the pharmaceutical preparation is suitable for administration to a human subject. 2. The pharmaceutical composition of claim 1 , wherein the ALK1-ECD protein comprises amino acid residues 22-118 of SEQ ID NO:1. 3. The pharmaceutical composition of claim 1 , wherein the ALK1-ECD protein comprises amino acid residues 22-120 of SEQ ID NO:1. 4. The pharmaceutical composition of claim 1 , wherein the ALK1-ECD protein is an ALK1-Fc fusion protein. 5. The pharmaceutical composition of claim 1 , wherein the ALK1-ECD protein comprises: a polypeptide having an amino acid sequence that is at least 85% identical to the sequence of amino acid residues 22-118 of SEQ ID NO:1. 6. The pharmaceutical composition of claim 1 , wherein the ALK1-ECD protein comprises: a polypeptide having an amino acid sequence that is at least 85% identical to the sequence of amino acid residues 22-120 of SEQ ID NO:1. 7. The pharmaceutical preparation of claim 1 , wherein the ALK1-ECD protein is produced by expression of the nucleic acid of SEQ ID NO:4 in a mammalian cell line. 8. The pharmaceutical preparation of claim 1 , wherein the ALK1-ECD protein is produced by expression of the nucleic acid of SEQ ID NO:4 in a Chinese Hamster Ovary (CHO) cell line. 9. The pharmaceutical preparation of claim 1 , wherein the pharmaceutical preparation is suitable for administration to the eye. 10. The pharmaceutical preparation of claim 1 , wherein at least 95% of the ALK1-ECD protein is present in a dimeric form. 11. The pharmaceutical preparation of claim 1 , wherein at least 99% of the ALK1-ECD protein is present in a dimeric form. 12. The pharmaceutical preparation of claim 1 , wherein the ALK1-ECD protein comprises a human ALK1-ECD protein. 13. The pharmaceutical preparation of claim 1 , wherein the ALK1-ECD protein comprises an amino acid sequence of at least 30 consecutive amino acids of an amino acid sequence of an extracellular portion of SEQ ID NO:1. 14. The pharmaceutical preparation of claim 1 , wherein the composition comprises at least 1 milligram of the ALK1-ECD protein per kilogram body weight of the subject. 15. The pharmaceutical preparation of claim 1 , wherein the pharmaceutical composition is substantially pyrogen-free. 16. The pharmaceutical preparation of claim 1 , wherein the ALK1-ECD protein binds to BMP9 or BMP10.
Assignees
Inventors
Classifications
Drugs for disorders of the cardiovascular system · CPC title
Antineoplastic agents · CPC title
Ophthalmic agents · CPC title
fusions with soluble part of a cell surface receptor, "decoy receptors" · CPC title
- C07K14/71Primary
for growth factors; for growth regulators · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10059756B2 cover?
- In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. Additionally, the disclosure demonstrates that inhibitors of ALK1 may be used to increase per…
- Who is the assignee on this patent?
- Grinberg Asya, Knopf John, Pearsall Robert S, and 4 more
- What technology area does this patent fall under?
- Primary CPC classification C07K14/71. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Aug 28 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 5 related publications on this page (citations in our corpus or others sharing the same primary CPC).